WBI Investments LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

WBI Investments LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, Holdings Channel reports. The firm bought 736 shares of the biopharmaceutical company’s stock, valued at approximately $414,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CoreCap Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 20 shares during the period. Strait & Sound Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 21 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares during the last quarter. MAI Capital Management raised its holdings in shares of Regeneron Pharmaceuticals by 2.1% during the 3rd quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 21 shares during the period. Finally, Independence Bank of Kentucky boosted its holdings in Regeneron Pharmaceuticals by 7.7% in the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after purchasing an additional 22 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0%

NASDAQ:REGN opened at $744.12 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market cap of $78.67 billion, a P/E ratio of 17.90, a PEG ratio of 2.04 and a beta of 0.41. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $767.89 and its 200-day simple moving average is $698.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Barclays started coverage on Regeneron Pharmaceuticals in a research report on Friday, March 6th. They issued an “overweight” rating and a $923.00 target price on the stock. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Scotiabank upped their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.